FA
BMY.RT

Financial Advantage’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Financial Advantage’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-29,885
Closed -$20K – 134
2020
Q4 		$20K Sell
29,885
-1,463
-5% -$3.12K 0.02% 90
2020
Q3 		$70K Sell
31,348
-11,305
-27% -$32.3K 0.07% 50
2020
Q2 		$152K Sell
42,653
-787
-2% -$2.84K 0.11% 35
2020
Q1 		$165K Sell
43,440
-1,370
-3% -$4.51K 0.14% 32
2019
Q4 		$134K Buy
+44,810
New +$117K 0.09% 38

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Financial Advantage's BMY.RT Position: Q1 2021 in Review

Financial Advantage sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 29,885 shares — an estimated $20K sold.

Financial Advantage first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $165K in Q1 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Financial Advantage reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Financial Advantage sold 29,885 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $20K.
  • Financial Advantage first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
  • Financial Advantage's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $165K in Q1 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Financial Advantage's 13F filing for Q1 2021, filed 4 May 2021.